The accelerated approval of Modeyso for diffuse midline glioma with an H3 K27M mutation, is a step in the right direction but more work remains. The accelerated approval from the U.S. Food and Drug ...

Phase 2 study shows proton therapy kept 79.1% of patients progression free at five years and limited severe side effects compared with older radiation data. Investigators at Mass General Brigham ...

Glioblastoma is the most prevalent and aggressive brain tumor. It proliferates very rapidly, is highly invasive, and there is currently no treatment capable of halting its progression or curing it, ...

Glioblastoma is the most prevalent and aggressive brain tumor. It proliferates very rapidly, is highly invasive, and there is currently no treatment capable of halting its progression or curing it, ...

Mass General Brigham study highlights the efficacy of proton therapy in reducing toxicity while enhancing outcomes for patients with lower grade gliomas compared to traditional radiotherapy A new ...

Purdue University researcher Mark Cushman serves as chief scientific officer, founder and board member for Gibson Oncology, a clinical-stage private pharmaceutical company. The company announced it ...

Former NBA center Jason Collins spent more than a decade in professional basketball. He also made history in 2013 as the first openly gay active player in a major American men’s professional sports ...